Oruka Therapeutics Says Psoriasis Drug Shows Deepening Efficacy
Oruka Therapeutics reports positive week 28 results from its Phase 2a trial for plaque psoriasis treatment ORKA-001.
Share
Why It Matters
Oruka's psoriasis medicine kept working well in longer testing. When a drug keeps helping patients more over time, it shows real promise to doctors and investors.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.